Myasthenia gravis, autoimmune acquired (Q88653): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Changed an Item
‎Changed an Item
 
Property / Collection date
 
13 August 2026
Timestamp+2026-08-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / Collection date: 13 August 2026 / rank
 
Normal rank

Latest revision as of 14:59, 15 August 2026

Acquired myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterised by fluctuating muscular weakness that often affects selected muscle groups preferentially. The pathophysiological result is muscle endplate dysfunction and consequent fatigable weakness. Subtypes are broadly classified as: early-onset myasthenia gravis (<50 years); late-onset myasthenia gravis (>50 years); thymoma-associated myasthenia gravis; myasthenia gravis with anti-muscle-specific receptor tyrosine kinase antibodies; ocular myasthenia gravis; myasthenia gravis with no detectable antibodies.
Language Label Description Also known as
default for all languages
ID_1205670816
    English
    Myasthenia gravis, autoimmune acquired
    Acquired myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterised by fluctuating muscular weakness that often affects selected muscle groups preferentially. The pathophysiological result is muscle endplate dysfunction and consequent fatigable weakness. Subtypes are broadly classified as: early-onset myasthenia gravis (<50 years); late-onset myasthenia gravis (>50 years); thymoma-associated myasthenia gravis; myasthenia gravis with anti-muscle-specific receptor tyrosine kinase antibodies; ocular myasthenia gravis; myasthenia gravis with no detectable antibodies.

      Statements

      CID11:ID_1205670816
      0 references
      dki-india-ID_1205670816
      0 references
      Concluído
      0 references
      13 August 2026
      0 references